Statin non-use and the nocebo effect: How can your patient’s reticence be overcome?

Website intended for a NZ health professional readership

+Practice

In print

HEARTBEAT

Statin non-use and the nocebo effect: How can your patient’s reticence be overcome?

3 March 2021

Chris Ellis

Wednesday 3 March 2021, 12:25 AM

Consultant cardiologist Chris Ellis discusses how to address a patient’s concerns about statin side effects, and the evidence and strategies useful to reassure them

Key points, Significant and harmful rhabdomyolysis with statin use is very rare. Between 85 and 95 per cent of patients using a statin have no difficulty with , Pract Green w Pale Yellow

Medicines and Therapies

References

Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial. JAMA 2016;315(5):1580–90.
Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med 2020;383(22):2182–84.

How to Treat

+How to treat

Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality

Wednesday 29 January 2025, 12:45 AM